a randomized trial assessing the safety and immunogenicity of as01 and as02 adjuvanted rts,s malaria vaccine candidates in children in gabon一项随机试验的安全性和免疫原性评估as01 as02佐剂的rts,s疟疾疫苗候选人在加蓬的儿童.pdfVIP

下载本文档

3
0
约6.01万字
约 9页
2017-09-05 发布于上海
举报
版权申诉

a randomized trial assessing the safety and immunogenicity of as01 and as02 adjuvanted rts,s malaria vaccine candidates in children in gabon一项随机试验的安全性和免疫原性评估as01 as02佐剂的rts,s疟疾疫苗候选人在加蓬的儿童.pdf

1、本文档共9页，可阅读全部内容。
2、有哪些信誉好的足球投注网站（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

a randomized trial assessing the safety and immunogenicity of as01 and as02 adjuvanted rts,s malaria vaccine candidates in children in gabon一项随机试验的安全性和免疫原性评估as01 as02佐剂的rts,s疟疾疫苗候选人在加蓬的儿童

A Randomized Trial Assessing the Safety and Immunogenicity of AS01 and AS02 Adjuvanted RTS,S Malaria Vaccine Candidates in Children in Gabon Bertrand Lell1,5*, Selidji Agnandji1,5, Isabelle von Glasenapp1,5, Sonja Haertle 1,5, Sunny Oyakhiromen1,5, 1,5 2 2 2 2 Saadou Issifou , Johan Vekemans , Amanda Leach , Marc Lievens , Marie-Claude Dubois , Marie-Ange 2 3 3 4 2 1,5 Demoitie , Terrell Carter , Tonya Villafana , W. Ripley Ballou , Joe Cohen , Peter G. Kremsner ´ ´ 1 Medical Research Unit, Albert Schweitzer Hospital, Lambarene, Gabon, 2 GlaxoSmithKline, Biologicals, Rixensart, Belgium, 3 PATH Malaria Vaccine Initiative, Bethesda, Maryland, United States of America, 4 Bill Melinda Gates Foundation, Seattle, Washington, United States of America, 5 Institute for Tropical Medicine, University of ¨ ¨ Tubingen, Tubingen, Germany Abstract Background: The malaria vaccine candidate antigen RTS,S includes parts of the pre-erythrocytic stage circumsporozoite protein fused to the Hepatitis B surface antigen. Two Adjuvant Systems are in development for this vaccine, an oil-in water emulsion – based formulation (AS02) and a formulation based on liposomes (AS01). Methods Principal Findings: In this Phase II, double-blind study (NC, 180 healthy Gabonese children aged 18 months to 4 years were randomized to receive either RTS,S/AS01 or RTS,S/AS02 , on a 0–1–2 month vaccination schedule. E D The chi